Silexion Therapeutics Unveils Promising Preclinical Results for SIL204

Silexion Therapeutics ( (SLXN) ) has provided an announcement.

On May 29, 2025, Silexion Therapeutics announced groundbreaking preclinical results for its RNAi therapeutic candidate, SIL204, showing strong efficacy in pancreatic, colorectal, and lung cancers. The preclinical data revealed that SIL204 effectively inhibited cancer cell proliferation and metabolic activity in KRAS G12D mutation-driven cancers, with significant results observed in a dose-dependent manner. These findings expand SIL204’s therapeutic potential beyond pancreatic cancer, highlighting its potential as a pan-KRAS therapy and underscoring the company’s innovative approach in addressing unmet medical needs in oncology.

The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for treating solid tumors driven by KRAS mutations, which are common oncogenic drivers in human cancers. The company is pioneering innovative treatments with its first-generation product, LODER™, and its next-generation candidate, SIL204, aimed at addressing a broader range of KRAS mutations.

Average Trading Volume: 3,098,756

Technical Sentiment Signal: Sell

Current Market Cap: $8.78M

Find detailed analytics on SLXN stock on TipRanks’ Stock Analysis page.